lancet-header
Preprints with The Lancet is part of SSRN´s First Look, a place where journals and other research experts identify content of interest prior to publication. These preprint papers are not peer-reviewed and are posted here as part of a 12-month trial. Authors have either opted in at submission to The Lancet family of journals to post their preprints on Preprints with The Lancet, or submitted directly via SSRN. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. These papers should not be used for clinical decision making or reporting of research to a lay audience without indicating that this is preliminary research that has not been peer-reviewed. For more information see the Comment published in The Lancet, or visit The Lancet´s FAQ page, and for any feedback please contact preprints@lancet.com

Comorbidities and Sex Differences in Causes of Death Among Mantle Cell Lymphoma Patients - A Nationwide Population-Based Cohort Study

35 Pages Posted: 15 Apr 2019

See all articles by Ingrid Glimelius

Ingrid Glimelius

Uppsala University - Department of Immunology, Genetics and Pathology, Clinical and Experimental Oncology; Uppsala University - Uppsala University Hospital; Karolinska Institutet - Karolinska University Hospital; Karolinska Institutet - Department of Medicine

Karin E. Smedby

Karolinska Institutet - Department of Medicine

Sandra Eloranta

Karolinska Institutet - Department of Medicine

Mats Jerkeman

Skane University Hospital

Caroline E. Weibull

Karolinska Institutet - Department of Medicine

More...

Abstract

Background: The prognosis for mantle cell lymphoma (MCL) remains poor, particularly for elderly patients. Our aim was to assess the impact of comorbidities on MCL outcome and causes of death.

Methods: For all 1,385 MCL patients (1,009 males, 376 females) diagnosed 2000-2014 in Sweden (median age 71 years, range 22-96) comorbidities within 10 years prior to diagnosis were classified according to the Charlson comorbidity index (CCI; 0, 1, 2+). Hazard ratios (HRs) with 95% confidence intervals (CIs) were estimated using flexible parametric models to compare rates of lymphoma-specific and all-cause-mortality by comorbidities. Model-based predictions were used to obtain probabilities of death from lymphoma/other causes.

Findings: Severe comorbidity was independently associated with higher all-cause (HR=1·52; 95% CI:1·24-1·85) and lymphoma-specific mortality (HR=1·.31; 95% CI:1·04-1·65), particularly among patients with connective tissue, renal, psychiatric diseases, and dementia. 606 patients (44%) had any comorbidity (CCI 1+) and 388 (28%) severe comorbidity (CCI 2+). Over a median follow-up of 3.7 years (range 0-16), 633 patients (46%) died, the majority (76%) from their lymphoma. Among females with comorbidities, non-lymphoma deaths represented a larger proportion of all deaths, as compared to comorbid males.

Interpretation: Since most MCL patients (including comorbid patients) died from lymphoma, more efficient and tolerable lymphoma treatments need to be considered also to patients with severe comorbidity. Patients with renal, psychiatric, or connective tissue disorders need particular attention. However, among females with comorbidities, the likelihood of dying from disorders other than MCL was still considerable, perhaps favoring a more liberal use of a "wait-and-watch" approach.

Funding Statement: This study was supported by the Swedish Cancer Society CAN (2012/774). I. Glimelius was supported by The Swedish Cancer Society (CAN 2016/440) and the Swedish Society of Medicine.

Declaration of Interests: MJ: Honoraria from Janssen, Gilead, Celgene, Roche, Acerta. Research support from Janssen, Celgene, Abbvie and Gilead. KES: Honoraria from Celgene. Research support from Janssen. IG Honoraria from Janssen. SE has an ongoing role as project manager in a publicprivate real world evidence collaboration between Karolinska Institutet and Janssen Pharmaceuticals NV (contract: 5-63/2015)

Ethics Approval Statement: The study was approved by the Regional Board of the Ethical Committee in Stockholm, Sweden (2007/1335-31/4, 2010/1624-32).

Keywords: Mantle Cell Lymphoma, Comorbidity, Sex, Lymphoma-specific mortality, Cause of death

Suggested Citation

Glimelius, Ingrid and Smedby, Karin E. and Eloranta, Sandra and Jerkeman, Mats and Weibull, Caroline E., Comorbidities and Sex Differences in Causes of Death Among Mantle Cell Lymphoma Patients - A Nationwide Population-Based Cohort Study (April 12, 2019). Available at SSRN: https://ssrn.com/abstract=3371081

Ingrid Glimelius (Contact Author)

Uppsala University - Department of Immunology, Genetics and Pathology, Clinical and Experimental Oncology ( email )

Sweden

Uppsala University - Uppsala University Hospital ( email )

Sweden

Karolinska Institutet - Karolinska University Hospital ( email )

Solna, 17176
Sweden

Karolinska Institutet - Department of Medicine ( email )

Stockholm, SE-171 76
Sweden

Karin E. Smedby

Karolinska Institutet - Department of Medicine

Stockholm, SE-171 76
Sweden

Sandra Eloranta

Karolinska Institutet - Department of Medicine

Stockholm, SE-171 76
Sweden

Mats Jerkeman

Skane University Hospital

Inga Marie Nilssons gata 47
214 21 Malmö
Sweden

Caroline E. Weibull

Karolinska Institutet - Department of Medicine

Stockholm, SE-171 76
Sweden

Click here to go to TheLancet.com

Go to TheLancet.com

Paper statistics

Abstract Views
12
Downloads
3